Deupirfenidone ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
85特発性間質性肺炎2

85. 特発性間質性肺炎


臨床試験数 : 627 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-006820-41-GR
(EUCTR)
23/12/202216/09/2022A Randomized Double-blind Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary FibrosisA Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF). Idiopathic Pulmonary Fibrosis (IPF);Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Name: deupirfenidone
Product Code: LYT-100
INN or Proposed INN: deupirfenidone
Other descriptive name: Pirfenidone, deuterated
Product Name: pirfenidone
INN or Proposed INN: Pirfenidone
Other descriptive name: Pirfenidone
PureTech LYT 100, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
240Phase 2Serbia;United States;Czechia;Taiwan;Greece;Thailand;Chile;Colombia;India;Mexico;Argentina;Malaysia;Poland;Romania;Georgia;Korea, Republic of
2NCT05321420
(ClinicalTrials.gov)
July 29, 20222/4/2022LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisDrug: Placebo;Drug: Pirfenidone;Drug: DeupirfenidonePureTechNULLRecruiting40 YearsN/AAll240Phase 2United States;Argentina;Georgia;Greece;India;Malaysia;Romania;Thailand